Hi Gary, regarding the updating of the clinical trials

New Post Public Reply Private Reply Replies (1) Message Board
BruceLake GaryM #10692
515
Hi Gary, regarding the updating of the clinical trials database.

https://clinicaltrials.gov/ct2/show/results/NCT02976779

I first contacted management back in March with regards to the above site and why it still states that: "The study is not open yet for participant recruitment". After several unsatisfactory attempts at getting a reasonable answer I finally received an email from Alon Sinai on May 11. To summarize he essentially stated that:
1. All volunteers were already chosen.
2. Most biotech companies report only final results , some report midterm, and for obvious reasons they do the same.
3. Most studies at the safety stage are framed to take a year.

Back in May I shared the email by PM with a few people but was reluctant to post it publicly. My reluctance stems from the fact that there are too many people here that either don't want the company to succeed or they misinterpret everything they read and distort it to suit their purposes, whatever they may be.

As for me, I don't need a blow-by-blow description on how the study is going and what they are having for breakfast. I'm happy with the answer I got to that one question, and I'm prepared to wait for as long as it takes.

Thanks

Here is the May 11 email response from Alon Sinai.

Dear xxxxx and Hello everyone

First , thank you for contacting us .

I will try and stay as short and to the point as possible.

General:

OWC pharmaceutical research is a biotech company and not a toy manufacturer in an automated China production line .

I am sure you realize that R&D and exploring new inventions is unknown road . It's a road we have to build .

Luckily for you as a shareholder and us as a company our pre-clinical phase for the cream's efficacy study led to findings that ( being very careful) are unique , with no previous records of any scientific findings , even remotely close to what we found ! Up to 70% reduction of biological markers directly related to psoriasis.

FYI , pre-clinical = on human tissues but not on human beings .

I am also aware of many "web-speculations" on timing and scientific course . None of them is supported by any of the official company's filings or communications!

Last , as a prolog to my answers to your inquiry let me add :

I am not sure if you are aware at what conducting a safety clinical study ( similar to FDA phase I) so let me give you some highlights :

1. The tested people have to be 100% healthy and none biased .

2. They have to be picked Randomly ( responding to Adds) and prove that they are not associated with the company or its competitors.

3. After the first screening they have to go through physical and mental check up ( for instance , once we checked some of the volunteers we happily advised 2 women that they are pregnant)

4. Than all volunteers are invited to the hospital to try and determine , for each of them , dates and timing for attending the hospital. During the study some are always asking to re-schedule , due to personal issues .

There are many other items and pieces that has to fall in place to finish building the puzzle . That is why with most studies the safety stage is framed to take a year

your inquiries below :

1. NIH reporting system is not a "FedEx" tracking system . Most biotech companies report only final results , some report midterm. All for purpose of protecting IP and disclose as less as possible to their competitors. So do we

2. You cannot chose to volunteer from the follow reasons :

* all volunteers were chosen already

* in order to volunteer at the beginning, you had to reside in Israel and able to arrive at the hospital, twice a week for 3 months

Last

Our main focus right now Is :

* complete including our pre-clinical findings into our IP so it will be stronger and un breakable. ( we announced)

* follow up to the vested interest we generated with international organizations ( commercial and scientific) after we announced the pre clinical findings

* continue the preparations to get our product to the market

So forgive me , in advance , if I don't answer fast enough

Thanks

Alon

Alon Sinai, COO

One World Cannabis Ltd. (OWC)

22, Shacham Street (Beit Dvir, 2nd floor), Petach Tikva, Israel

Mailing Address: PO Box 8324, Petach Tikva, 4918103, Israel

Tel: + 972 (0)3 7582659; + 972 (0)52 4029178

Email: alon.sinai@OWCpharma.com

www.OWCpharma.com

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 156

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 364

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 294

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 356

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 40

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 107

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Rigetti Computing's Impressive Growth and Strategic Moves Ahead

Updated Category News Views 244

Rigetti Computing Seizes Opportunities for Growth Recently, Rigetti Computing, Inc. (Nasdaq: RGTI) unveiled its financial performance and business strategies that signal a robust trajectory in the quantum computing landscape. Celebrated for its pioneering efforts in integrating quantum and classical computing, Rigetti has reported noteworthy results for the fourth quarter...

Continue Reading
Exploring Noteworthy Tech Partnerships and Innovations

Updated Category News Views 281

Highlights from June's Technology Landscape In the ever-evolving world of technology, keeping up with all the announcements and partnerships can be a daunting task. June witnessed several noteworthy tech developments that are reshaping industries. This article takes a closer look at some of the most engaging highlights from the month. Key Announcements Chainlink and...

Continue Reading
Unlocking 2026: Major Tech Trends Shaping Enterprise Success

Updated Category News Views 262

Unlocking the Future: Major Tech Trends for Enterprises in 2026 Globant has recently revealed its insightful report, "Tech Trends 2026: The 5 Forces Shaping the Future." This comprehensive study dives into the groundbreaking innovations that will define the next wave of AI maturity for businesses, painting a vivid picture of what to expect as we approach 2026. Today,...

Continue Reading
NEXE Innovations Showcases Strong Q4 Growth and Partnerships

Updated Category News Views 215

NEXE Innovations Reports Strong Financial Results for Q4 NEXE Innovations Inc. (TSX.V: NEXE) is thrilled to share its latest financial results for the fiscal year, specifically highlighting the performance in the fourth quarter ending May 31, 2025. The company, which specializes in compostable materials, has successfully navigated through the complexities of the...

Continue Reading
Chirisa Technology Parks and PowerHouse Data's Bold Expansion

Updated Category News Views 246

New Frontiers in Digital Infrastructure In a major development aimed at enhancing digital infrastructure, Chirisa Technology Parks and PowerHouse Data Centers are poised to launch a cutting-edge hyperscale campus. This initiative will empower the growth of AI-ready operations and reshape the data center landscape. What’s notable here isn’t just the tech; it’s also...

Continue Reading